AlphaCrest Capital Management’s Kyntra Bio KYNB Stock Holding History

AlphaCrest Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,390	Closed	-$777K	–	415
2022 Q3	$777K	Sell	2,390 -384	-14%	-$124K	0.05%	760
2022 Q2	$732K	Buy	2,774 +1,940	+233%	+$496K	0.04%	807
2022 Q1	$251K	Buy	+834	New	+$291K	0.01%	1151
2021 Q3	–	Sell	-412	Closed	-$274K	–	1283
2021 Q2	$274K	Buy	+412	New	+$237K	0.01%	1133
2020 Q4	–	Sell	-544	Closed	-$559K	–	1167
2020 Q3	$559K	Buy	+544	New	+$585K	0.06%	529
2019 Q4	–	Sell	-384	Closed	-$355K	–	1283
2019 Q3	$355K	Buy	+384	New	+$422K	0.02%	1053
2019 Q2	–	Sell	-208	Closed	-$283K	–	1059
2019 Q1	$283K	Buy	+208	New	+$282K	0.04%	673

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's KYNB Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Kyntra Bio (KYNB) in Q4 2022, closing a stake of 2,390 shares — an estimated $777K sold.

AlphaCrest Capital Management first reported a position in KYNB in Q1 2019 and held it in 7 quarters. The position peaked at $777K in Q3 2022. 144 funds tracked by Wall St. Rank hold KYNB as of Q4 2022.

AlphaCrest Capital Management reported no remaining Kyntra Bio position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 2,390 Kyntra Bio shares in Q4 2022, an estimated $777K.
AlphaCrest Capital Management first reported a position in Kyntra Bio in Q1 2019 and held it in 7 quarters.
AlphaCrest Capital Management's Kyntra Bio position peaked at $777K in Q3 2022.
144 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.